Tempus AI, Inc. (BCBA:TEM)
Argentina · Delayed Price · Currency is ARS | Market Cap | 18.68T -21.5% |
| Revenue (ttm) | 2.12T +50.4% |
| Net Income | -376.93B |
| EPS | -2,123.99 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,626 |
| Open | 9,110.00 |
| Previous Close | 9,580.00 |
| Day's Range | 8,905.00 - 9,250.00 |
| 52-Week Range | 5,165.00 - 12,360.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 30, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced the launch of GenomeNext™ and...
Tempus AI price target raised to $95 from $80 at Canaccord
Canaccord raised the firm’s price target on Tempus AI (TEM) to $95 from $80 and keeps a Buy rating on the shares. The firm sees increasing utilization of and a…
Tempus AI price target raised to $75 from $52 at BofA
BofA raised the firm’s price target on Tempus AI (TEM) to $75 from $52 and keeps a Neutral rating on the shares as part of a specialty diagnostics group preview…
Tempus AI announces multi-year collaboration with Moderna, Merck
Tempus (TEM) announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy bein...
Tempus Announces Multi-Year Collaboration with Moderna and Merck
CHICAGO--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potent...
Tempus AI price target raised to $92 from $65 at Guggenheim
Guggenheim analyst Subbu Nambi raised the firm’s price target on Tempus AI (TEM) to $92 from $65 and keeps a Buy rating on the shares. The firm adjusted its models…
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking ...
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Tempus AI receives FDA clearance for ECG-MR AI product
Tempus AI (TEM) has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms to detect signs asso...
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes...
Tempus AI, Recursion extend data license agreement, enter new license agreement
Tempus AI (TEM) announced an extension of its data license agreement with Recursion Pharmaceuticals (RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will li...
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies ...
Tempus AI initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Tempus AI (TEM) with a Neutral rating and $75 price target The company offers “highly visible” near-term growth in its diagnostics business but faces mid-term…
Tempus AI stock is soaring: does it have more upside to go?
Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization ab...
Tempus AI Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong demand in diagnostics and data licensing, FDA approvals, and strategic acquisitions are driving robust growth and margin expansion. AI adoption and partnerships position the company for continued leadership in oncology and data-driven healthcare, with significant upside from latent demand and new markets.
Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AI
Eric Lefkofsky, Tempus AI founder and CEO, joins 'The Exchange' to discuss AI's role in healthcare, advancing cancer research with AI, personalized vaccines, and more.
REVOLUTIONIZING HEALTHCARE: Tempus partners with Merck on AI-driven precision medicine
Tempus CEO Eric Lefkofsky discusses the company's artificial intelligence-driven precision medicine partnership with Merck on ‘The Claman Countdown.'
Tempus AI to build multimodal whole-genome dataset for AI-driven healthcare
Tempus AI (TEM) announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. The effort will create th...
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the...
Tempus AI price target raised to $66 from $56 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Tempus AI (TEM) to $66 from $56 and keeps a Buy rating on the shares. The firm says Merck’s…
Tempus AI awarded up to $9.5M from ARPA-H for autonomous AI in cardiology
Tempus AI (TEM) announced that it has been selected by the Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services, to receive…
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of ...